<DOC>
	<DOCNO>NCT01263470</DOCNO>
	<brief_summary>The purpose study evaluate dose-response relationship alogliptin , daily ( QD ) α-glucosidase inhibitor , three time daily ( TID ) , determine optimal clinical dose type 2 diabetic patient .</brief_summary>
	<brief_title>Efficacy Safety Alogliptin Participants With Type 2 Diabetes Japan</brief_title>
	<detailed_description>Both insulin hyposecretion insulin-resistance consider involved development type 2 diabetes mellitus . Takeda develop SYR-322 ( alogliptin ) improvement glycemic control patient type 2 diabetes mellitus . Alogliptin inhibitor dipeptidyl peptidase IV ( DPP-IV ) enzyme . DPP-IV think primarily responsible degradation 2 peptide hormone release response nutrient ingestion . It expect inhibition DPP-IV improve glycemic control patient type 2 diabetes . To evaluate long-term safety efficacy alogliptin , participant present study could enter long-term extension study SYR-322/OCT-001 ( NCT01263496 ) plan separately .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<criteria>A glycosylated hemoglobin ( HbA1c ) value 6.5 % 10.0 % 4 week start screen ( Week −4 ) . A HbA1c difference within 10.0 % * ( *rounded first decimal point ) start screening ( Week −8 ) 4 week start screen ( Week −4 ) HbA1c value start screen . Was receive specific diet therapy exercise therapy ( ) last 4 week longer start screen ( Week −8 ) . Received antidiabetic drug within last 4 week start screen ( Week −8 ) screening .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Diabetes Mellitus - Type 2</keyword>
	<keyword>Diabetes Mellitus</keyword>
	<keyword>Drug Therapy</keyword>
</DOC>